RPG LifeScience. Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.4K Cr
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry). Domestic formulation growth expected at ~12% annually, driven by volume expansion and new product launches, especially in cardiology, urology, and pain management. - API segment projected to grow 9-10% with a strong pipeline of 13 products and new market entries; Q4 FY26 showed a 144% bounce back in API revenues. - International formulation segment anticipated to return to growth following temporary inventory rationalization and regulatory improvements. - Volume-driven growth prioritized over price increases, with volumes growing 9.8% vs.
From RPG LifeScience.'s Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Price
₹2,564
Market Cap
₹4.4K Cr
P/E Ratio
37.4
Revenue Rank
Margin Rank
How does RPG LifeScience. rank in Pharmaceuticals & Biotechnology?
Compare RPG LifeScience. against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
RPG LifeScience. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹177 Cr, net profit ₹30 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry).
- →Focus on volume-backed growth rather than relying on price increases, especially as 30% of products fall under DPCO (Drug Price Control Order).
- →New products in pipeline expected to launch with higher gross margins, enabling better price growth than previous years.
- →International formulation segment poised for growth from FY27 onwards after temporary inventory rationalization, with expansion into new markets like Africa.
- →API business seen as a significant medium-term growth driver, with 144% Q4 bounce back and a strong pipeline of 13 new products; consistent 9-10% growth expected.
- →Emphasis on expanding through new customers, markets, and products in emerging and regulated markets.
- →Long-term strategy includes both organic growth and value-accretive inorganic opportunities (M&A).
📈 Profitability & Margins
Rank 3- →Domestic formulation growth expected at ~12% annually, driven by volume expansion and new product launches, especially in cardiology, urology, and pain management.
- →API segment projected to grow 9-10% with a strong pipeline of 13 products and new market entries; Q4 FY26 showed a 144% bounce back in API revenues.
- →International formulation segment anticipated to return to growth following temporary inventory rationalization and regulatory improvements.
- →Volume-driven growth prioritized over price increases, with volumes growing 9.8% vs. industry 1.1%, and new products contributing 5.1% growth.
- →Gross margins expected to stabilize/improve with full API plant operations resuming and higher-margin new product launches.
- →Cautious approach to US FDA approvals, only pursuing when a significant product basket is ready to avoid disproportionate costs.
- →Overall, sustained operating earnings and EPS growth supported by robust volume growth, new product introductions, operational efficiencies, and diversified market presence.
🏗️ Capital Expenditure Plans
Yes- →RPG Life Sciences has invested over INR 140 crores in capex over the last 4-5 years, focusing on modernizing and expanding facilities to drive cost efficiencies and position for future growth (Page 5).
- →The company continues to invest in strengthening organizational capabilities and leadership pipeline via succession planning and capability-building initiatives (Page 6).
- →Strategic focus is on both organic and inorganic growth, with the company actively looking for prudent, value-accretive inorganic opportunities in formulations and API business through M&A (Page 10).
- →Investments include expansion into newer markets, increased R&D capabilities, and capacity building in both domestic and international formulations as well as API segments (Pages 4-5, 10).
- →The management emphasizes cautious approach towards investments like U.S. FDA approvals only when significant product baskets justify the costs (Page 11).
💰 Fundraising & Capital Structure
No information- →There is no specific mention of any current or planned new fundraising through debt or equity in the provided transcript.
- →The company maintains a strong balance sheet with a cash surplus of approximately INR 275 crores.
- →They have invested over INR 140 crores capex over the last 4-5 years, funded prudently without indicating new external funding needs.
- →The management emphasizes prudent capital deployment, focusing on organic and inorganic growth without discussing immediate debt or equity raising plans.
- →The company aims to remain mindful of cost-benefit equations and avoid unnecessary profit and loss burdens, especially regarding U.S. FDA approval-related expenses.
📋 Order Book & Pipeline
Yes- →RPG Life Sciences did not explicitly disclose specific numbers or values regarding their current or expected order book or pending orders during the conference call.
- →However, management highlighted a strong growth pipeline both domestically and internationally with:
- → - New product launches in domestic markets, including cardiology, urology, and pain management.
- → - International Formulation (IF) segment developing 5 CDMO projects, with 3 expected this year and 2 in FY28.
- → - R&D pipeline with 10 molecules in IF and 13 products in API segment.
- →Inventory rationalization in international formulations by some customers was described as a temporary blip, with stable order flow expected going forward.
- →The company remains focused on expanding customer relationships, increasing market presence, and launching new products across markets.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were RPG LifeScience. Q4 FY26 results?
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry). Domestic formulation growth expected at ~12% annually, driven by volume expansion and new product launches, especially in cardiology, urology, and pain management. - API segment projected to grow 9-10% with a strong pipeline of 13 products and new market entries; Q4 FY26 showed a 144% bounce back in API revenues. - International formulation segment anticipated to return to growth following temporary inventory rationalization and regulatory improvements. - Volume-driven growth prioritized over price increases, with volumes growing 9.8% vs.
What is RPG LifeScience. share price analysis?
RPG LifeScience. currently shows a below-average growth signal. The stock trades at a P/E of 37.4 with a market cap of ₹4,361 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG LifeScience. planning capital expenditure?
RPG Life Sciences has invested over INR 140 crores in capex over the last 4-5 years, focusing on modernizing and expanding facilities to drive cost efficiencies and position for future growth (Page 5). - The company continues to invest in strengthening organizational capabilities and leadership pipeline via succession planning and capability-building initiatives (Page 6). - Strategic focus is on both organic and inorganic growth, with the company actively looking for prudent, value-accretive inorganic opportunities in formulations and API business through M&A (Page 10). - Investments include expansion into newer markets, increased R&D capabilities, and capacity building in both domestic and international formulations as well as API segments (Pages 4-5, 10). - The management emphasizes cautious approach towards investments like U.S.
Keep RPG LifeScience. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.